Results 21 to 30 of about 21,590 (76)

Atypical infections during combination therapy with anifrolumab and other immunosuppressives in patients with lupus erythematosus: A case series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Shae Chambers, Lais Lopes Almeida Gomes, Xiwei Yang, Aretha On, Hammad Ali, Touraj Khosravi‐Hafshejani, Kimberly DeQuattro, Preethi Thomas, Victoria P. Werth   +8 more
wiley   +1 more source

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia

eJHaem, Volume 6, Issue 3, June 2025.
ABSTRACT Background Real‐world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited. Methods We evaluated outcomes of patients with newly‐diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95).
Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza‐Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Ravi Bhatia, Omer Jamy   +9 more
wiley   +1 more source

Lack of Evidence for the Efficacy of Antifungal Medications to Treat Atopic Dermatitis: A Systematic Review

JEADV Clinical Practice, Volume 4, Issue 2, Page 400-406, June 2025.
This systematic review evaluated the efficacy of antifungal therapies for atopic dermatitis (AD). Of 35,591 studies screened, seven met inclusion criteria. Topical antifungals, such as sertaconazole and miconazole, showed limited benefit compared to placebo or hydrocortisone. Oral antifungals, including itraconazole and ketoconazole, demonstrated mixed
Luis F. Andrade, Teresa Ju, Parsa Abdi, Michael R. Anderson, Elise Edwards, Nicole Khalil, Olivia Burke, Daniella Jaguan, Jonathan I. Silverberg   +8 more
wiley   +1 more source

An international survey of recalcitrant and recurrent tinea of the glabrous skin—A potential indicator of antifungal resistance

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1185-1191, June 2025.
Abstract Background There has been a global rise in cases of dermatophytosis and, in particular, recalcitrant and recurrent cases on tinea of the glabrous skin. This phenomenon, particularly prevalent in India, has been linked to the concerning rise of antifungal resistance. The challenge is amplified by a dearth of comprehensive, international data to
Sidra S. Khan, Roderick Hay, Ditte Marie L. Saunte   +2 more
wiley   +1 more source

Natural History of Idiosyncratic Drug‐Induced Liver Injury and Prognostic Models

Liver International, Volume 45, Issue 6, June 2025.
ABSTRACT Background and Aims: Drug‐induced liver injury (DILI) remains a leading cause of acute liver failure worldwide. Drugs such as isoniazid, alone or in combination with other anti‐tuberculosis drugs, as well as a growing number of herbal and complementary medicines, have been implicated in most cases of acute liver failure in registry studies ...
Harshad C. Devarbhavi, Raúl J. Andrade
wiley   +1 more source

Comparative efficacy of selenoureido carbonic anhydrase inhibitors and azole antifungal drugs against clinical isolates of Malassezia pachydermatis

Veterinary Dermatology, Volume 36, Issue 3, Page 302-313, June 2025.
Background – Malassezia pachydermatis (MP) is implicated in severe dermatitis and otitis externa (OE) of companion animals and recently gained attention for its increasing resistance to azole compounds. For this reason, developing novel therapeutic strategies is of great interest. In a previous work, we used reference yeast isolates to evaluate several
Costanza Spadini, Nicolò Mezzasalma, Amienwanlen Eugene Odigie, Andrea Angeli, Fabrizio Carta, Silvia Selleri, Emanuele Gandolfo, Simone Taddei, Valentina Franceschi, Sergio Minesso, Claudiu T. Supuran, Clotilde Silvia Cabassi   +11 more
wiley   +1 more source

Effect of CYP3A4 inhibitor and induction on the pharmacokinetics and safety of FHND9041, a novel EGFR T790M inhibitor, in healthy Chinese. [PDF]

BMC Pharmacol Toxicol
Lu C, Cheng D, Xie Y, Shang M, Chen R, Zhu Y, Gong J, Zhou H.   +7 more
europepmc   +1 more source

Observational study of the recent efficacy and economy of itraconazole vs. voriconazole in perioperative pulmonary aspergillosis. [PDF]

Front Surg
Chen P, Zhang X, Zheng X, Tang Y, Song Y, Xu G, Ke X, Chen C.   +7 more
europepmc   +1 more source

Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism. [PDF]

Front Pharmacol
Han M, Cui G, Zhao Y, Zuo X, Wang X, Zhang X, Mi N, Jin J, Xiao C, Wang J, Wu W, Li Y, Li J.   +12 more
europepmc   +1 more source

Itraconazole-associated purpuric drug eruption: a rare adverse effect of a commonly prescribed drug. [PDF]

Skin Health Dis
Mathur M, Regmi S, Paudel S, Paudel S, Bhattarai N, Karki S.   +5 more
europepmc   +1 more source